Metagenomi Therapeutics, Inc. MGX
1.15
0.00
0.00%
as of 25 Sep
- Market cap
- $43.4M
- P/E
- 0.0×
Follow MGX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.86 | 2.39 | 2.26 | 3.30 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.16) | (2.56) | (2.38) | (2.30) | |
P/B ratio |
0.50 | 0.38 | 0.37 | 0.40 | |
Price to Tangible BV |
0.50 | 0.38 | 0.37 | 0.40 | |
EV/Sales |
(2.11) | (2.78) | (2.67) | (3.36) | |
EV/EBITDA |
0.72 | 0.75 | 0.66 | 0.47 | |
EV/Operating CF |
0.71 | 0.79 | 0.68 | 0.53 | |
EV/FCF |
0.71 | 0.78 | 0.68 | 0.53 | |
Quick Ratio |
6.26 | 7.03 | 6.23 | 4.37 | |
Current Ratio |
6.42 | 7.22 | 6.43 | 4.50 | |
Net Debt/EBITDA |
8.24 | 6.83 | 5.92 | 4.46 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.10 | 0.09 | 0.09 | 0.06 | |
Operating CF/Net income |
1.04 | 1.05 | 0.92 | 0.71 | |
Capex/Depreciation |
(0.15) | (0.10) | (0.03) | (0.07) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
291.99% | 549.76% | 1,546.47% | (8,759.53%) | |
Selling, General and Administrative Expense of Revenue |
71.78% | 173.28% | 523.64% | (2,336.19%) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
34.76% | 68.88% | 204.49% | (882.49%) | |
Graham Net Nets |
1.36 | 1.71 | 1.70 | 1.41 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(101.27%) | (146.30%) | (171.64%) | (209.24%) | |
Free Cash Flow Yield |
(104.39%) | (148.19%) | (173.75%) | (191.45%) | |
Revenue per Share |
0.23 | 0.11 | 0.03 | (0.01) | |
Operating CF per Share |
(0.57) | (0.63) | (0.56) | (0.52) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.57) | (0.63) | (0.56) | (0.52) | |
Cash per Share |
4.93 | 4.32 | 3.73 | 3.20 | |
Shareholders Equity per Share |
4.78 | 4.26 | 3.67 | 2.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.78 | 4.26 | 3.67 | 2.99 | |
Free Cash Flow |
(21.33) | (23.63) | (21.20) | (19.64) | |
Working Capital |
160.24 | 142.61 | 122.06 | 96.84 | |
Capital Expenditures |
(0.07) | (0.08) | (0.02) | (0.12) | |
Net Current Asset Value |
120.33 | 103.03 | 85.39 | 63.33 | |
EV/EBIT |
0.71 | 0.73 | 0.64 | 0.45 | |
Capex to Sales |
0.01 | 0.02 | 0.02 | (0.49) | |
Net Profit Margin |
(235.51%) | (576.02%) | (1,847.68%) | 10,693.39% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.77 | 0.78 | — | — | |
Average Payables |
2.16 | 1.01 | 2.53 | 2.75 | |
Average Assets |
303.14 | 272.85 | 247.41 | 222.99 | |
Average Common Equity |
217.11 | 196.73 | 175.22 | 154.20 |
Columns are period end dates